Designing a First-in-Human Dose-Escalation and Dose-Optimization Study of an Oral Covalent KRAS G12C Inhibitor: Translational and Regulatory Strategy and Phase 1 Protocol Synopsis

Early oncology development has moved away from treating the maximum tolerated dose as the default recommended dose, and a covalent inhibitor whose effect depends on how much of a rapidly resynthesized target it occupies is a case in which that shift matters. This article develops the translational and regulatory strategy and a complete protocol synopsis for a hypothetical first-in-human study of a second-generation oral covalent KRAS G12C inhibitor in adults with advanced solid tumors. It derives a 100 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks (rat STD10 and dog HNSTD), verifies the arithmetic, and sets five dose levels from 100 to 800 mg under a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, after a seven-day single-dose pharmacokinetic run-in. Part B randomizes about 30 patients with lung cancer between two candidate doses to compare exposure-response, target occupancy, and tolerability before a recommended Phase 2 dose is chosen. The synopsis specifies eligibility, schedules, dose-limiting toxicity rules, and stopping rules including exposure ceilings, and states every assumed value as an assumption.Keywords: first-in-human; KRAS G12C; covalent inhibitor; ICH S9; BOIN design; dose optimization; target occupancy; Phase 1 protocol

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426679
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Dose-Escalation and Dose-Optimization Study of an Oral Covalent KRAS G12C Inhibitor: Translational and Regulatory Strategy and Phase 1 Protocol Synopsis

Mounika Battula, Peivand Pirouzi
Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

Designing a First-in-Human Dose-Escalation and Dose-Optimization Study of an Oral Covalent KRAS G12C Inhibitor: Translational and Regulatory Strategy and Phase 1 Protocol Synopsis

Mounika Battula, Peivand Pirouzi
article en

Abstract

Early oncology development has moved away from treating the maximum tolerated dose as the default recommended dose, and a covalent inhibitor whose effect depends on how much of a rapidly resynthesized target it occupies is a case in which that shift matters. This article develops the translational and regulatory strategy and a complete protocol synopsis for a hypothetical first-in-human study of a second-generation oral covalent KRAS G12C inhibitor in adults with advanced solid tumors. It derives a 100 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks (rat STD10 and dog HNSTD), verifies the arithmetic, and sets five dose levels from 100 to 800 mg under a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, after a seven-day single-dose pharmacokinetic run-in. Part B randomizes about 30 patients with lung cancer between two candidate doses to compare exposure-response, target occupancy, and tolerability before a recommended Phase 2 dose is chosen. The synopsis specifies eligibility, schedules, dose-limiting toxicity rules, and stopping rules including exposure ceilings, and states every assumed value as an assumption.Keywords: first-in-human; KRAS G12C; covalent inhibitor; ICH S9; BOIN design; dose optimization; target occupancy; Phase 1 protocol

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon